ATE209916T1 - Orale zubereitungen von antimykotika - Google Patents

Orale zubereitungen von antimykotika

Info

Publication number
ATE209916T1
ATE209916T1 AT94927639T AT94927639T ATE209916T1 AT E209916 T1 ATE209916 T1 AT E209916T1 AT 94927639 T AT94927639 T AT 94927639T AT 94927639 T AT94927639 T AT 94927639T AT E209916 T1 ATE209916 T1 AT E209916T1
Authority
AT
Austria
Prior art keywords
antifungals
oral preparations
preparations
oral
Prior art date
Application number
AT94927639T
Other languages
English (en)
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE209916T1 publication Critical patent/ATE209916T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT94927639T 1993-09-30 1994-09-22 Orale zubereitungen von antimykotika ATE209916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12950493A 1993-09-30 1993-09-30
PCT/EP1994/003169 WO1995008993A1 (en) 1993-09-30 1994-09-22 Oral formulations of an antifungal

Publications (1)

Publication Number Publication Date
ATE209916T1 true ATE209916T1 (de) 2001-12-15

Family

ID=22440301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927639T ATE209916T1 (de) 1993-09-30 1994-09-22 Orale zubereitungen von antimykotika

Country Status (30)

Country Link
US (1) US5707975A (de)
EP (1) EP0721337B1 (de)
JP (1) JP3034048B2 (de)
CN (1) CN1086579C (de)
AP (1) AP630A (de)
AT (1) ATE209916T1 (de)
AU (1) AU692180B2 (de)
CA (1) CA2170622C (de)
CY (1) CY2272B1 (de)
CZ (1) CZ288026B6 (de)
DE (1) DE69429359T2 (de)
DK (1) DK0721337T3 (de)
ES (1) ES2169087T3 (de)
FI (1) FI115443B (de)
HU (1) HU221632B1 (de)
IL (1) IL111093A (de)
MY (1) MY111136A (de)
NO (1) NO308985B1 (de)
NZ (1) NZ273619A (de)
OA (1) OA10276A (de)
PH (1) PH31594A (de)
PL (1) PL313731A1 (de)
PT (1) PT721337E (de)
RO (1) RO115114B1 (de)
RU (1) RU2118899C1 (de)
SG (1) SG48826A1 (de)
SK (1) SK282627B6 (de)
TW (1) TW349870B (de)
WO (1) WO1995008993A1 (de)
ZA (1) ZA947619B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243994T5 (es) 1996-04-19 2009-10-29 Grifols Inc. Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
DE69838338T2 (de) 1997-10-22 2008-05-21 Jens Rochester Ponikau Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
ES2251985T3 (es) 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
EP1169024B1 (de) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
CA2291346A1 (en) 1999-11-26 2001-05-26 Bernard Charles Sherman Antifungal solutions
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US6673373B2 (en) 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
WO2002072102A1 (en) 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
RU2205644C1 (ru) * 2002-02-18 2003-06-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1511490A4 (de) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc Neue kristalline conazol-formen und verwandte prozesse, pharmazeutische zusammensetzungen und verfahren
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
CA2440172C (en) * 2003-09-05 2011-01-11 Bernard Charles Sherman Itraconazole solution
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
GR1005154B (el) 2005-02-09 2006-03-13 Verisfield (Uk) Ltd. Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον
JP2009502258A (ja) * 2005-07-21 2009-01-29 ノミール・メディカル・テクノロジーズ・インコーポレーテッド 標的部位の生物学的汚染物質のレベルを下げる方法
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症(mucormycosis)及其他真菌類疾病之組合物及方法
MX2009003911A (es) 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
US20100233101A1 (en) 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
NZ614255A (en) 2009-03-19 2015-03-27 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
ES2565353T3 (es) * 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
CN102670490A (zh) * 2012-05-10 2012-09-19 南京特丰药业股份有限公司 一种伊曲康唑口服溶液及其制备方法
CN103230363A (zh) * 2013-03-29 2013-08-07 湖北凤凰白云山药业有限公司 一种抗真菌的口服溶液
CA3020197C (en) 2017-09-01 2024-06-04 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
RU2707286C1 (ru) * 2019-07-02 2019-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения
CN114191387A (zh) * 2021-12-26 2022-03-18 苏州海景医药科技有限公司 一种伏立康唑口服液的制备方法
CN114191386B (zh) * 2021-12-26 2024-03-12 苏州海景医药科技有限公司 一种波生坦口服溶液的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2033086T3 (es) * 1988-01-29 1993-03-01 Sankyo Company Limited Un procedimiento para la preparacion de una composicion farmaceutica.
SU1708343A1 (ru) * 1989-09-22 1992-01-30 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ получени твердых лекарственных форм
RU2127733C1 (ru) * 1992-03-18 1999-03-20 Жансен Фармасетика Н.В. Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе

Also Published As

Publication number Publication date
HU9600804D0 (en) 1996-05-28
AP9600792A0 (en) 1996-04-30
FI115443B (fi) 2005-05-13
WO1995008993A1 (en) 1995-04-06
HK1010689A1 (en) 1999-06-25
CN1136776A (zh) 1996-11-27
NO961233D0 (no) 1996-03-27
EP0721337A1 (de) 1996-07-17
DK0721337T3 (da) 2002-03-25
CZ288026B6 (cs) 2001-04-11
CZ82396A3 (en) 1996-06-12
CN1086579C (zh) 2002-06-26
ES2169087T3 (es) 2002-07-01
MY111136A (en) 1999-08-30
AP630A (en) 1998-03-10
PT721337E (pt) 2002-05-31
JPH09502989A (ja) 1997-03-25
NO961233L (no) 1996-03-27
DE69429359T2 (de) 2002-07-25
AU7697994A (en) 1995-04-18
HUT74378A (en) 1996-12-30
SG48826A1 (en) 1998-05-18
RU2118899C1 (ru) 1998-09-20
PL313731A1 (en) 1996-07-22
PH31594A (en) 1998-11-03
JP3034048B2 (ja) 2000-04-17
US5707975A (en) 1998-01-13
CY2272B1 (en) 2003-07-04
IL111093A0 (en) 1994-11-28
OA10276A (en) 1997-10-07
TW349870B (en) 1999-01-11
FI961436A0 (fi) 1996-03-29
FI961436L (fi) 1996-03-29
EP0721337B1 (de) 2001-12-05
NO308985B1 (no) 2000-11-27
RO115114B1 (ro) 1999-11-30
ZA947619B (en) 1996-03-29
AU692180B2 (en) 1998-06-04
IL111093A (en) 2001-01-28
DE69429359D1 (de) 2002-01-17
HU221632B1 (hu) 2002-12-28
CA2170622C (en) 1999-07-27
CA2170622A1 (en) 1995-04-06
NZ273619A (en) 1997-06-24
SK39996A3 (en) 1996-12-04
SK282627B6 (sk) 2002-10-08

Similar Documents

Publication Publication Date Title
ATE209916T1 (de) Orale zubereitungen von antimykotika
FI932282L (fi) Protein c-derivat
DK91192D0 (da) Protein
DE19681287T1 (de) Orale Formulierung von 2-Methylthienobenzodiazepin
DE69518331D1 (de) Orale zubereitungen
KR950703926A (ko) 화장제 조성물(Cosmetic Composition)
DK314089A (da) Orale praeparater
DK19991D0 (da) Proteinpraeparationer
FI952574A7 (fi) Glykosyylitransferaasiaktiiviset proteiinit
DE59407063D1 (de) Deodorierende zubereitungen
DE69328575D1 (de) Dermatologische Präparate
ATE232397T1 (de) Neuartige orale zubereitungen von calcitonin
DK132892D0 (da) Proteiner
FI934863L (fi) Vid rustemperatur tvaerbindande kopolymerer
DE69429514D1 (de) Antiparasitäre präparate
DE69432149D1 (de) Orale Zubereitungen
FI933892L (fi) Topiskt tvaolgelpreparat
FI930812L (fi) Ny sulfatiserad diosminderivat
FI932327A0 (fi) Tvaettningsstation monterad vid en lucka
FI934090A7 (fi) Huvudstroembrytare vid en elektrisk hushaollsapparat
FI924871A0 (fi) Anordning vid en virvelstroemsbroms foer en konditionsanordning
DK120792D0 (da) Protein
KR940021704U (ko) 케이프
KR930026760U (ko) Tvcr의 개선된 구성
BR9306699A (pt) Derivados do triazoliletanol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification